Skip to main content
Premium Trial:

Request an Annual Quote

Epic Sciences Raises $40M in Series D Financing Round

NEW YORK (GenomeWeb) – Epic Sciences said today that it has completed a $40 million Series D financing.

Hermed Capital led the round, which also included Altos Capital Partners, Domain Associates, Genomic Health, Pagoda Investment, Reach Tone Limited, RMI Partners, Sabby Capital, and VI Ventures.

Epic said it plans to use the funds to accelerate clinical validation of its pipeline of oncology tests, which is led by the firm's AR-v7 prostate cancer assay, now being commercialized in partnership with Genomic Health as OncotypeDx AR-V7 Nucleus Detect.

The money will also help Epic work to enhance its proprietary "No Cell Left Behind" technology to include characterization of rare leukocyte cell populations using digital imaging and big data analytics, the firm said. The company hopes this will allow the platform to glean insights into the cellular drivers of response or resistance to new therapeutics like cancer immunotherapies.

The Scan

Wolf Howl Responses Offer Look at Vocal Behavior-Related Selection in Dogs

In dozens of domestic dogs listening to wolf vocalizations, researchers in Communication Biology see responses varying with age, sex, reproductive status, and a breed's evolutionary distance from wolves.

Facial Imaging-Based Genetic Diagnoses Appears to Get Boost With Three-Dimensional Approach

With data for more than 1,900 individuals affected by a range of genetic conditions, researchers compared facial phenotype-based diagnoses informed by 2D or 3D images in the European Journal of Human Genetics.

Survey Suggests Multigene Cancer Panel VUS Reporting May Vary Across Genetic Counselors

Investigators surveyed dozens of genetic counselors working in clinical or laboratory settings, uncovering attitudes around VUS reporting after multigene cancer panel testing in the Journal of Genetic Counseling.

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.